Femasys Inc. (FEMY) experienced a decrease of 8.21% in aftermarket despite any official news. However, the last trading session closed at $3.29 with an increase of 10.03%.
Publication of Clinical Data – Latest News
On 1st February 2022, it was announced the publishing of data about patients having awake plastic surgery. The team has published the article with the title “Awake Plastic Surgery Procedures” in the journal named Aesthetic Surgery Journal Open Forum.
The advantages of awake plastic surgery include patient preference, affordability, and easier recovery. Moreover, oral analgesics often used are frequently insufficient to provide effective analgesia for these procedures. Furthermore, the findings of this study show that giving a single dose of SST 30 minutes before awake plastic surgery procedures can provide effective pain management with a low rate of adverse events.
What’s Next?
DSUVIA provides advantages to patients and clinicians in a variety of surgical conditions. FEMY is working hard to see the outcomes of several ongoing studies that will provide more real-world proof of DSUVIA’s uses.
FEMY: Appointment of Wendy Perrow – Worth it?
FEMY announced on 20th January 2022 that Wendy Perrow has been appointed as a new board member. Wendy offers a strong and established strong reputation of topline vision and management consulting, and also high-level tactical skills in marketing, business and product development, and financing, to the board. Moreover, all of this will be really helpful as the company moves forward with the commercial assets as the key product candidates continue to progress in clinical trials.
FEMY: Third Quarter 2021 Financial Results – How was the quarter?
FEMY reported third-quarter 2021 financial results on 10th November 2021. The company experienced research and developments costs of about $144,957 with a 14.6% increase. Moreover, the general and administrative expenses inclined by 82.2% and reached $490,585. Unfortunately, the sales of FEMY’s product i.e., FemVue experienced a downfall of 13.9% reaching almost $43,627. Lastly, net loss came out to be $2,259,701.
So what?
FEMY is getting ready for the pivotal trial for FemBloc. It is the permanent birth control product candidate, that will take place next year in conjunction with the anticipated IDE submission. FEMY is keen to address the existing constraints of infertility and birth control alternatives. They both are enormous and underserved markets within women’s reproductive health globally.
